4-((2-nitrophenyl)amino)benzonitrile | 117847-17-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-((2-nitrophenyl)amino)benzonitrile
• 英文别名: 4-(2-Nitroanilino)benzonitrile
• CAS: 117847-17-3
• 化学式: C₁₃H₉N₃O₂
• 分子量: 239.233
• InChiKey: LNSGQBLIXAOEQR-UHFFFAOYSA-N

物化性质

• 沸点：
  421.0±30.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  81.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((2-nitrophenyl)amino)benzonitrile 在 palladium on activated charcoal 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 8.0h， 以88%的产率得到4-(2-aminophenylamino)benzonitrile
  参考文献：
  名称：

  Side chain effects on the solid-state emission behaviours and mechano-fluorochromic activities of 10H-phenothiazinylbenzo[d]imidazoles

  摘要：

  研究了具有不同侧链的10-苯并[d]咪唑基苯并噻吩的固态发光行为和MFC性能。

  DOI：

  10.1039/c9ra05255k
• 作为产物：
  描述：

  对氯苯甲腈 、 2-硝基苯胺 在 sodium phenoxide 、 C₅₀H₇₂ClPPd 、 2,6-bis(2,4,6-triisopropylphenyl)phenyldicyclohexylphosphine 作用下， 以 叔丁醇 为溶剂， 反应 12.0h， 以84%的产率得到4-((2-nitrophenyl)amino)benzonitrile
  参考文献：
  名称：

  三联苯膦作为钯催化芳基卤与 1°苯胺胺化的高效配体

  摘要：

  已开发出三联苯膦配体（2,6-双（2,4,6-三异丙基苯基）苯基-二环己基膦，TXPhos）及其负载的钯配合物[(TXPhos)(allyl)PdCl]，该催化剂体系在芳基卤化物与 1° 苯胺的胺化，对密集官能化的底物特别有效，包括具有原酸酯、乙酰基、腈和硝基的两个伙伴。使用TXPhos负载的催化剂体系，前所未有地实现了许多合作伙伴的组合，基础范围甚至扩展到了KOAc，这甚至是2-硝基氯苯胺化的最佳选择。

  DOI：

  10.1016/j.jcat.2021.08.017

文献信息

• [EN] SUBSTITUTED DIHYDRO-BENZIMIDAZOLE COMPOUNDS AS ROR GAMMA MODULATORS<br/>[FR] UTILISATION DE COMPOSÉS SUBSTITUÉS DIHYDRO-BENZIMIDAZOLE COMME MODULATEURS DU ROR GAMMA
  申请人：GLENMARK PHARMACEUTICALS SA

  公开号：WO2015052675A1

  公开（公告）日：2015-04-16

  The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as modulator of retinoid-related orphan receptor gamma t (RORyt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated disease, disorder, syndrome or condition such as pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases or cancer.

  本公开涉及式(I)的化合物及其药用盐，作为视黄醇相关孤儿受体γt（RORγt）的调节剂。这些化合物可以预防、抑制或抑制RORγt的作用，因此在治疗由RORγt介导的疾病、紊乱、综合症或病况，如疼痛、炎症、慢性阻塞性肺病（COPD）、哮喘、类风湿性关节炎、结肠炎、多发性硬化、神经退行性疾病或癌症方面具有用处。
• Selenium‐Catalyzed Carbonylative Synthesis of 2‐Benzimidazolones from 2‐Nitroanilines with TFBen as the CO Source
  作者：Xinxin Qi、Rong Zhou、Jin‐Bao Peng、Jun Ying、Xiao‐Feng Wu

  DOI：10.1002/ejoc.201801739

  日期：2019.9

  A selenium‐catalyzed carbonylative reaction for the synthesis of 2‐benzimidazolones from 2‐nitroanilines has been developed. In this strategy, to avoid the usage of toxic CO gas, TFBen (benzene‐1,3,5‐triyl triformate) was used as a solid and stable CO precursor, and a variety of desired 2‐benzimidazolones were produced in moderate to excellent yields.

  已开发了一种硒催化的羰基化反应，用于从2-硝基苯胺合成2-苯并咪唑酮。在此策略中，为避免使用有毒的CO气体，TFBen（苯-1,3,5-三甲酸酯三甲酸酯）被用作固体和稳定的CO前体，并且生产了各种所需的2-苯并咪唑酮，其中中等至极好。产量。
• 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors
  作者：Upul Bandarage、Brian Hare、Jonathan Parsons、Ly Pham、Craig Marhefka、Guy Bemis、Qing Tang、Cameron Stuver Moody、Steve Rodems、Sundeep Shah、Chris Adams、Jose Bravo、Emmanuelle Charonnet、Vladimir Savic、Jon H. Come、Jeremy Green

  DOI：10.1016/j.bmcl.2009.07.022

  日期：2009.9

  We report herein the design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivatives as inhibitors of p70S6 kinase. Screening hits containing the 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine scaffold were optimized for p70S6K potency and selectivity against related kinases. Structure-based design employing an active site homology model derived from PKA led to the preparation of benzimidazole 5-substituted compounds 26 and 27 as highly potent inhibitors (K-i < 1 nM) of p70S6K, with > 100-fold selectivity against PKA, ROCK and GSK3. (C) 2009 Elsevier Ltd. All rights reserved.
• Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists
  作者：Pradip K. Sasmal、Sanjita Sasmal、P. Tirumala Rao、B. Venkatesham、M. Roshaiah、Chandrasekhar Abbineni、Ish Khanna、Vikram P. Jadhav、J. Suresh、Rashmi Talwar、Syed Muzeeb、Jean-Marie Receveur、Thomas M. Frimurer、Øystein Rist、Lisbeth Elster、Thomas Högberg

  DOI：10.1016/j.bmcl.2010.07.086

  日期：2010.9

  Melanin concentrating hormone (MCH) is an important mediator of energy homeostasis and plays role in several disorders such as obesity, stress, depression and anxiety. The synthesis and biological evaluation of novel benzimidazole derivatives as MCHR1 antagonists are described. The in vivo proof of principle for weight loss with a lead compound from this series is exemplified. (c) 2010 Elsevier Ltd. All rights reserved.
• Gorvin, John H., Journal of the Chemical Society. Perkin transactions I, 1988, p. 1331 - 1336
  作者：Gorvin, John H.

  DOI：——

  日期：——